OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press62010.17650/1818-8346-2007-0-1-39-41THERAPY OF HEMATOLOGIC MALIGNANCIESТЕРАПИЯ ГЕМОБЛАСТОЗОВTreatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the CD52 antigen (Campath) - the first Russian experienceЛимфолейкоза с аутоиммунными осложнениями антителами против антигена CD52 (кэмпас)ByalikT. E.БяликТ. Е.
Russian Federation

Moscow

Москва

TimofeevaO. L.ТимофееваО. Л.
Russian Federation

Moscow

Москва

VolkovaM. A.ВолковаМ. А.
Russian Federation

Moscow

Москва

N.N. Blokhin Russian Cancer Research Centre, Russian Academy of Medical SciencesГУ РОНЦ им. Н.Н. Блохина, РАМН220220071394122112022221120222007https://oncohematology.abvpress.ru/ongm/article/view/620

Campath is a humanized monoclonal antibody targeted to the CD52 antigen. It shows efficacy with response rate of 35% in treatment of patients with chronic lymphocytic leukemia (CLL) who were refractory to fludarabine. A first-line therapy with Campath demonstrates efficacy in more than 80% of CLL patients. Campath deserves a special emphasis due to effectiveness in different autoimmune cytope-nias. We describe 2 cases of CLL and autoimmune thrombocytopenia, treated with Campath. Both patients received 36 infusions of Campath. There were no severe leucopenia or anemia as well as serious infections. Stable platelet count recovery, no evidence of antiplatelet antibodies and elimination of bone marrow lymphoid infiltration were achieved after the end of the treatment.

Кэмпас — это гуманизированные антитела против антигена CD52. Эффективность лечения кэмпасом больных хроническим лимфолейкозом, рефрактерных к флударабину, составляет 35%. В качестве первой линии кэмпас эффективен более чем в 80% случаев. Особого внимания заслуживает эффективность применения кэмпаса при различных аутоиммунных цитопениях. Мы представляем 2 случая хронического лимфолейкоза с наличием аутоиммунной тромбоцитопении. Оба больных получили 36 введений кэмпаса, глубоких лейкопении и анемии не было, серьезных инфекций тоже. После завершения лечения у больных наблюдались стойкое восстановление уровня тромбоцитов, исчезновение антитромбоцитарных антител, ликвидация лимфоидной инфильтрации костного мозга.

CD52Campathchronic lymphocytic leukaemiaautoimmune thrombocytopeniaCD52кэмпасхронический лимфолейкозаутоиммунная тромбоцитопения1. O' Brien S. Clinical challenges in chronic lymhocytic leukemia. Semin Hematol 1998; 35 (3 Suppl 3):22—6.O' Brien S. Clinical challenges in chronic lymhocytic leukemia. Semin Hematol 1998; 35 (3 Suppl 3):22—6.2. Keating M., O' Brien S., Albitar M. et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophocsphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079—88.Keating M., O' Brien S., Albitar M. et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophocsphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079—88.3. Keating M.J., Kantarjan H. Combinaion therapy in CLL. Leukemia 2000 Towards the cure. Program and abstract book 2000 p. 28, abstr. S31.Keating M.J., Kantarjan H. Combinaion therapy in CLL. Leukemia 2000 Towards the cure. Program and abstract book 2000 p. 28, abstr. S31.4. Rossmann E., Lundun J., Leukei R. еt al. Variability n B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001;2:300—6.Rossmann E., Lundun J., Leukei R. еt al. Variability n B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol J 2001;2:300—6.5. Keating M., Flinn I., Jaun V. et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who failed flu-darabine: results of a large international study. Blood 2002;99:3554—61.Keating M., Flinn I., Jaun V. et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who failed flu-darabine: results of a large international study. Blood 2002;99:3554—61.6. Moreton P., Kennedy B., Lucas G. et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23(13):2971—9.Moreton P., Kennedy B., Lucas G. et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005;23(13):2971—9.7. Lundun J., Kimby E., Bjorholm M. et.al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patient with B-cell chronic lymphocytic leukemia ( B-CLL). Blood 2002;100 (3):768—73.Lundun J., Kimby E., Bjorholm M. et.al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patient with B-cell chronic lymphocytic leukemia ( B-CLL). Blood 2002;100 (3):768—73.8. Wfendhner C., Ritgen M., Schweighofer C. et al. Consolidation with alemtuzumab in patient with chronic lymphocytic leukemia (CLL) n first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Croup (GCLLSG). Leukemia 2004;18:1093—101.Wfendhner C., Ritgen M., Schweighofer C. et al. Consolidation with alemtuzumab in patient with chronic lymphocytic leukemia (CLL) n first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Croup (GCLLSG). Leukemia 2004;18:1093—101.9. Dyer M., Kelsey S., Mackay H. et al. In vivo purging of residual disease in CLL with Campath-1H. Br J Haematol 1997;97:669—72.Dyer M., Kelsey S., Mackay H. et al. In vivo purging of residual disease in CLL with Campath-1H. Br J Haematol 1997;97:669—72.10. Losanski G., Heerema N., Flinn I. et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutation and deletions. Blood 2004;103:3278—81.Losanski G., Heerema N., Flinn I. et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutation and deletions. Blood 2004;103:3278—81.11. Osuji N., Del Giudice I., Matutes E. et al. Alemtuzumab for chronic lymphocytic leukemia with and without p53 deletions. Blood 2004;104 (Suppl 1):688a; abstr. 2510.Osuji N., Del Giudice I., Matutes E. et al. Alemtuzumab for chronic lymphocytic leukemia with and without p53 deletions. Blood 2004;104 (Suppl 1):688a; abstr. 2510.12. Marsh J., Gordon-Smith E. Campath-1H in the treatment of autoimmune cytopenias. Cytotherapy 2001;3 (3):189—95.Marsh J., Gordon-Smith E. Campath-1H in the treatment of autoimmune cytopenias. Cytotherapy 2001;3 (3):189—95.13. Lundin J., Porwit McDonald A., Rossmann E. et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukemia ( B-CLL). Leukemia 2004;18:484—90.Lundin J., Porwit McDonald A., Rossmann E. et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukemia ( B-CLL). Leukemia 2004;18:484—90.14. Perkins J., Flynn J., Howard R. et al. Frequency and type of serious and small lymphocytic lymphoma: implication for clinical trials in this patient population. Cancer 2002;94:2033—9.Perkins J., Flynn J., Howard R. et al. Frequency and type of serious and small lymphocytic lymphoma: implication for clinical trials in this patient population. Cancer 2002;94:2033—9.